As a consequence of this mutational landscape, MCL cells are highly dependent on cell cycle (CCND1, RB1), DNA damage response (ATM, TP53), and NF-κB pathways for their survival, allowing the identification of several putative therapeutic targets among these signaling axes. The gene discussed is RB1; the disease is mantle cell lymphoma.